Osterweis Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Osterweis Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-144,461	Closed	-$4.57M	–	144
2021 Q1	$4.57M	Buy	144,461 +6,480	+5%	+$269K	0.25%	93
2020 Q4	$6.4M	Sell	137,981 -19,770	-13%	-$785K	0.38%	75
2020 Q3	$5.19M	Buy	157,751 +23,360	+17%	+$716K	0.35%	71
2020 Q2	$3.69M	Buy	134,391 +15,970	+13%	+$525K	0.27%	81
2020 Q1	$3.54M	Sell	118,421 -19,904	-14%	-$528K	0.29%	67
2019 Q4	$3.83M	Sell	138,325 -12,085	-8%	-$275K	0.26%	70
2019 Q3	$2.74M	Buy	150,410 +5,030	+3%	+$111K	0.2%	76
2019 Q2	$3.56M	Sell	145,380 -243,615	-63%	-$3.67M	0.25%	67
2019 Q1	$3.7M	Buy	+388,995	New	+$3.78M	0.23%	76
2018 Q4	–	Sell	-454,295	Closed	-$5.11M	–	107
2018 Q3	$5.11M	Buy	+454,295	New	+$6.45M	0.33%	71

Other funds holding IOVA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Osterweis Capital Management's IOVA Position: Q2 2021 in Review

Osterweis Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2021, closing a stake of 144,461 shares — an estimated $4.57M sold.

Osterweis Capital Management first reported a position in IOVA in Q3 2018 and held it in 10 quarters. The position peaked at $6.4M in Q4 2020. 233 funds tracked by Wall St. Rank hold IOVA as of Q2 2021.

Osterweis Capital Management reported no remaining Iovance Biotherapeutics position as of Q2 2021 after selling out during the quarter.
Osterweis Capital Management sold 144,461 Iovance Biotherapeutics shares in Q2 2021, an estimated $4.57M.
Osterweis Capital Management first reported a position in Iovance Biotherapeutics in Q3 2018 and held it in 10 quarters.
Osterweis Capital Management's Iovance Biotherapeutics position peaked at $6.4M in Q4 2020.
233 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2021.

Based on Osterweis Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.